This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.
Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright
by Kinjel Shah
The Zacks Large Cap Pharmaceuticals industry underperforms the sector and S&P 500. However it ranks in the top 19% of more than 250 Zacks industries.
Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Opdivo and Eliquis along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $81.21 in the latest trading session, marking a -0.22% move from the prior day.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Top Ranked Growth Stocks to Buy for July 22nd
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 22nd
Caterpillar (CAT) Set to Report Q2 Earnings: What to Expect
by Christopher Vargas
Caterpillar (CAT) is a company that has had somewhat of a quiet year, with shares up 7.7% year-to-date.
Is a Beat in the Cards for Bristol-Myers (BMY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top- and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports second-quarter results.
Bristol-Myers, Ono, Bayer Team Up for Colorectal Cancer Study
by Zacks Equity Research
Bristol-Myers (BMY), Ono Pharmaceutical and Bayer ink a collaboration deal to evaluate the combination of Opdivo plus Stivarga for treating micro-satellite stable metastatic colorectal cancer.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Dow 30 Stock Roundup: MSFT, JPM, IBM, JNJ, GS Earnings Impress
by Swarup Gupta
The Dow endured a volatile week, primarily due to renewed trade tensions, after gaining strongly earlier this month
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
by Kinjel Shah
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines segment is likely to witness sales growth in the second quarter.
Novartis (NVS) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Novartis (NVS) beats sales estimates in the second quarter, driven by robust performance of key drugs and biosimilars.
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
Merck's Antibiotic Recarbrio Gets FDA Nod for Infections
by Zacks Equity Research
The FDA approves Merck's (MRK) anti-bacterial injection, MK-7655A, to be marketed as Recarbrio.
Mallinckrodt (MNK) Discontinues Sclerosis Study on Acthar Gel
by Zacks Equity Research
Mallinckrodt (MNK) halts its phase IIB study, assessing the efficacy and safety of Acthar Gel as an investigational treatment for amyotrophic lateral sclerosis.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $81.59, moving +0.78% from the previous trading session.
Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
by Ekta Bagri
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
Glaxo's Zejula Meets Goal in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer meets the primary endpoint.
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco, Home Depot, Merck, Humana and Public Service Enterprise
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
by Zacks Equity Research
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.